Get the Stockscreener App
4.51
2.59%
-0.12
After Hours:
4.51
Immatics N V stock is traded at $4.51, with a volume of 494.83K.
It is down -2.59% in the last 24 hours and up +2.97% over the past month.
See More
Previous Close:
$4.63
Open:
$4.54
24h Volume:
494.83K
Relative Volume:
0.57
Market Cap:
$572.50M
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-3.47
EPS:
-1.2997
Net Cash Flow:
$-13.78M
1W Performance:
-9.80%
1M Performance:
+2.97%
6M Performance:
-60.47%
1Y Performance:
-57.09%
1-Day Range:
$4.35
$4.58
1-Week Range:
$4.35
$5.21
52-Week Range:
$4.18
$13.77
Immatics N V Stock (IMTX) Company Profile
Compare IMTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
4.51 | 572.50M | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Q1 Earnings Estimate for Immatics Issued By Leerink Partnrs - Defense World
Immatics Reports Strong 2024 Financial Results and Progress - TipRanks
Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.74, revenue topped estimates - Investing.com
Immatics NV reports results for the quarter ended December 31Earnings Summary - TradingView
Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire
Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials - TipRanks
Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - Stock Titan
Immatics (NASDAQ:IMTX) Trading Down 5.3% – Time to Sell? - Defense World
IMMATICS N.V Earnings Preview: Recent $IMTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
(IMTX) Trading Report - Stock Traders Daily
Immatics (IMTX) Projected to Post Earnings on Thursday - Defense World
Short Interest in Immatics (NASDAQ:IMTX) Declines By 11.9% - Defense World
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.
Y Intercept Hong Kong Ltd Buys New Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - Simply Wall St
Immatics N.V (IMTX) Recovers -2.54% From Low: Are We There Yet? - Stocks Register
Financial Metrics Unveiled: Immatics N.V (IMTX)’s Key Ratios in the Spotlight - The Dwinnex
Immatics (NASDAQ:IMTX) Sets New 1-Year Low – What’s Next? - Defense World
(IMTX) Trading Signals - Stock Traders Daily
Immatics (NASDAQ:IMTX) Reaches New 1-Year LowHere's What Happened - MarketBeat
abrdn plc Buys 114,479 Shares of Immatics (NASDAQ:IMTX) - MarketBeat
Immatics (NASDAQ:IMTX) Trading Down 4.7% – What’s Next? - Defense World
Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year - Yahoo Finance
Immatics N.V (IMTX): An Important Analyst Insights - Stocks Register
Financial Metrics Check: Immatics N.V (IMTX)’s Ratios for Trailing Twelve Months - The Dwinnex
Immatics (NASDAQ:IMTX) Reaches New 52-Week LowTime to Sell? - MarketBeat
Examining Immatics N.V (IMTX) more closely is necessary - US Post News
It is Poised to be a Bull Market for Immatics N.V (IMTX) - SETE News
Immatics N.V (IMTX) Becoming More Attractive for Investors - Knox Daily
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in January - MarketBeat
Immatics (NASDAQ:IMTX) Hits New 52-Week LowShould You Sell? - MarketBeat
Immatics N.V (IMTX) Volatility Hits 4.72% – Here Is What You Should Do - Stocks Register
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Immatics (NASDAQ:IMTX) - Defense World
Brokers Offer Predictions for Immatics FY2025 Earnings - ETF Daily News
Cantor Fitzgerald Predicts Immatics FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts Immatics FY2025 Earnings - MarketBeat
Is Immatics N.V. (IMTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in December - MarketBeat
Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World
Immatics (NASDAQ:IMTX) Shares Down 3.9%What's Next? - MarketBeat
Down -16.85% in 4 Weeks, Here's Why Immatics (IMTX) Looks Ripe for a Turnaround - Yahoo Finance
Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price - Simply Wall St
Immatics N.V.: Considering More Engineered T Cells For Cancer (NASDAQ:IMTX) - Seeking Alpha
IMTX: 3 Small-Cap Healthcare Stocks With Big Upside Potential - StockNews.com
Analyzing Immatics (NASDAQ:IMTX) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):